SCHEMBL6287210

SCHEMBL6287210

CC(C)(C)OC(=O)C([O])c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.46
ATM Q13315 1/20 0.46
KMT2A Q03164 4/20 0.46
AAK1 Q2M2I8 1/20 0.42
CTSS P25774 1/20 0.42
CTSK P43235 1/20 0.42
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 2/20 0.40
MAPT P10636 2/20 0.40
RECQL P46063 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
LMNA P02545 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
RIPK1 Q13546 1/20 0.39
ITGA4 P13612 1/20 0.39
ITGB7 P26010 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL355454 0.83 CES2 (0.53) L3MBTL1ATMKMT2AAAK1CTSS
SCHEMBL7043298 0.82 L3MBTL1 (0.55) L3MBTL1ATMKMT2AAAK1CTSS
SCHEMBL17965782 0.82 SRC (0.50) L3MBTL1ATMKMT2AAAK1CTSS
SCHEMBL27970498 0.81 ATM (0.44) L3MBTL1ATMKMT2AAAK1CTSS
SCHEMBL6287222 0.81 LMNA (0.52) L3MBTL1ATMKMT2AAAK1CTSS
SCHEMBL16782694 0.81 APP (0.47) L3MBTL1ATMKMT2AAAK1CTSS
SCHEMBL18207061 0.81 LMNA (0.52) L3MBTL1ATMKMT2AAAK1CTSS
SCHEMBL8593879 0.81 LMNA (0.52) L3MBTL1ATMKMT2AAAK1CTSS
SCHEMBL2289610 0.81 APP (0.47) L3MBTL1ATMKMT2AAAK1CTSS
SCHEMBL3335866 0.79 SRC (0.57) L3MBTL1ATMKMT2AAAK1CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1863770-B Cyclic amine BASE-1 inhibitors having a heterocyclic substituent SCHERING CORP 2011-05-25 CN disclosed
CN-1863797-A Cyclic amine BACE-1 inhibitors having a benzamide substituent PHARMACOPEIA DRUG DISCOVERY (US) 2006-11-15 CN disclosed
CN-1863770-A Cyclic amine BASE-1 inhibitors having a heterocyclic substituent SCHERING CORP AND PHARMACOPEIA (US) 2006-11-15 CN disclosed
US-6911468-B2 Tyrosine phosphatase inhibitors TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-06-28 US disclosed
US-20030144338-A1 Tyrosine phosphatase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-07-31 US disclosed
EP-1284260-A1 TYROSINE PHOSPHATASE INHIBITORS Takeda Chemical Industries, Ltd. (JP) 2003-02-19 EP disclosed
US-5505936-A ANTI-SUNTAN OR ANTI-SUNBURN OIL BASED COSMETICS KAO CORPORATION (JP) 1996-04-09 US disclosed
EP-0629630-A1 Novel phosphoric diesters which absorb UV rays, method of preparing the same, and cosmetic compositions containing the same KAO CORPORATION (JP) 1994-12-21 EP disclosed
US-4438277-A Hydronaphthalene derivatives SANKYO COMPANY, LIMITED (JP) 1984-03-20 US disclosed
US-4361515-A Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use SANKYO COMPANY, LIMITED (JP) 1982-11-30 US disclosed
US-4352928-A ANTIINFLAMMATORY, HYPOGLYCEMIC, ANTICOAGULANT, ANOREXIGENIC, SEROTONIN EFFEC MITSUBISHI YUKA PHARMACEUTICAL CO., LTD. (JP) 1982-10-05 US disclosed
EP-0022481-A1 5,6-Alkylenepyrimidine derivatives, processes for preparing the same and pharmaceutical compositions Mitsubishi Yuka Pharmaceutical Co., Ltd. (JP) 1981-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144338-A1 Tyrosine phosphatase inhibitors PTPRC, PTPN1, PTPRM L3MBTL1 1502/4885ATM 1709/4885KMT2A 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.